Canadian grants & funding programs

Research Project Grant (Parent R01 Clinical Trial Required)

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

United States

Population Dynamics Centers Research Infrastructure Program FY 2024 (P2C Clinical Trial Not Allowed)

The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

United States

NIMH Instrumentation Program (S10 Clinical Trial Not Allowed)

Reissue of RFA-MH-20-555. The NIMH Instrumentation Program encourages applications from NIH funded investigators to purchase or upgrade a single commercially available instrument or a group of components to create an instrument that is not commercially available. Examples of instruments that might be submitted under this Funding Opportunity Announcement (FOA) include light microscopes, electron microscopes, spectrophotometers, and biomedical imagers.

United States

Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.

United States

Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

The objective of this Notice of Funding Opportunity (NOFO) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety, and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.

United States

Leading Edge Acceleration Projects for Health IT (LEAP)

This Notice of Funding Opportunity (NOFO) seeks Leading Edge Acceleration Projects (LEAP) in Health Information Technology (Health IT) to address well-documented and fast emerging challenges inhibiting the development, use, and/or advancement of well-designed, interoperable health IT, which is scalable across the health care industry. Solutions are expected to further a new generation of health IT research and inform the development, implementation, and refinement of standards, methods, and techniques for overcoming major barriers and challenges in an innovative fashion as they are identified. It is critical that the field of health care innovate and leverage the latest technological advancements and breakthroughs far quicker than it currently does to optimize real-time solutions, especially in areas which are ripe for acceleration. Additional information and guidance for FY23 funding will be released by way of a Special Emphasis Notice.

United States

Time-Sensitive Opportunities for Health Research (R61/R33 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support research to understand health outcomes related to an unexpected and/or time-sensitive event (e.g., emergent environmental threat; pandemic; change in local, state, or national policy; natural disaster). Applications in response to this FOA must demonstrate that the research proposed is time-sensitive and must be initiated with minimum delay due to a limited window of opportunity to collect baseline data, answer key research questions, and/or prospectively evaluate a new policy or program. This FOA is intended to support opportunities in which empirical study could only be available through expedited review and funding, necessitating a substantially shorter process than the typical NIH grant review/award cycle. The time from submission to award is expected to occur within 4-5 months. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

United States

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigans National Addiction and HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Researchs (ICPSR) website.

United States

Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)

The NIH ?Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.

United States

Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional)

The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs). By providing such an opportunity for longer term support to ESIs, the NCI intends to offer flexibility and opportunity for creativity and innovation and additional time to successfully launch their careers and to become more established before having to submit renewal applications (NOT-CA-18-037). The objective of the NCI's ESI MERIT Award is to allow eligible investigators the opportunity to obtain up to 7 years of support in two segments:

United States

Yukon Government – Enterprise Trade Fund (ETF)

Covers up to 50% of eligible costs; maximum typically up to $50,000 per applicant per year.

Supports Yukon businesses undertaking market development and export activities, including marketing, trade shows, and commercialization planning for new products/services.

Yukon

LRCC – Metis Women Entrepreneurship Program

70% funding for equipment, marketing, and operational costs to grow your Métis business.

Métis Women Entrepreneurship (MWE) Grant & Loan Program provides commercial financing to help Métis Women start or expand businesses in Manitoba. This program offers up to $50,000.00 in financing composed of a grant and loan.

Manitoba

OCI Customer Demonstration Program

75% funding for technology development, marketing, and collaboration to boost your business.

The Customer Demonstration Program provides Ontario government grants to support technology demonstrations between two or more Ontario-based businesses. Through the program, funding will be awarded for innovative “market disruptors” to demonstrate the value of smart computing products/services to a “receptor” who can purchase and adopt the technology. This helps overcome commercialization barriers and helps generate a business case for wide-scale adoption.

Ontario

Centers for AIDS Research (P30 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

United States

Development of Animal Models and Related Biological Materials for Down Syndrome Research (R24 Clinical Trials Not-Allowed)

The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project encourages grant applications aimed at developing, characterizing, or improving animal models and related biological materials for Down syndrome (DS) related research and improving access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning (ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research.

United States

Terrorism and Targeted Violence Research and Evaluation

S&T seeks to support foundational research that contributes to advancing the state of the science through novel, nuanced, innovative and rigorous scientific inquiry using diverse and non-traditional strategies. This notice of funding opportunity (NOFO) aims to:. . Conduct basic and applied research to improve our understanding of how and why individuals radicalize to violence, mobilize to violence, and disengage from violence using diverse and non-traditional research strategies from a multi-disciplinary perspective.. . 2.    Understand the efficacy of non-government, online interventions to prevent, deter, or otherwise mitigate negative outcomes and harms related to online behaviors as they are related to Homeland Security missions.Please note that any activities conducted for research purposes must include an independent and objective evaluation component to understand outcomes and, if possible, impacts of interventions that are measurable and repeatable.. . 3.Ensure key stakeholders such as federal, state, local, tribal, and territorial partners, community-based organizations, violence prevention practitioners, and members of the public have the knowledge and tools required to support the implementation of effective prevention and intervention programming.. . This NOFO will prioritize investigations of historical terrorist and targeted violence acts, events, and movements that occur within the United States and its territories, or that targets its citizens specifically. The focus of this NOFO is to advance the understanding of behaviors and motivations to engage in terrorist or targeted violence activities, to inform greater understanding and provide situational awareness regarding terrorist movements, and to inform the creation of prevention, diversion, and rehabilitation strategies for those involved. Proposals focused on traditional counter terrorism or state-sponsored adversarial behaviors will not be prioritized. Proposals that seek to predict future patterns of behavior or threats will not be prioritized. 

United States

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR XX-XXX .

United States

Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. These grants are expected to foster the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.

United States

City of Montreal – Technological Test Beds Program

Financial contribution for eligible pilot and demonstration costs, up to $50,000.

Supports companies that want to test innovative technologies in real-life environments on City of Montreal assets or with municipal partners. Ideal for pilots and demonstrations to validate solutions.

Montreal · Quebec

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

This FOA solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

United States

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow candidates to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

United States

Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune systemdevelopment patterns between two or more age groups- neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on ontogeny and development of pediatric immune system, from birth, transitioning into adolescence and adulthood with focus impact during pregnancy and post-natal period.

United States

OCI - Communitech AVIN ($50K; Q3 2020)

33% funding for product development, prototype creation, and market traction.

A funding program that provides financial assistance to small and medium-sized enterprises (SMEs) in Ontario to help them develop innovative technologies and products related to advanced vehicles. The Communitech AVIN program is administered by Communitech, a non-profit organization that supports the growth and development of technology companies in the Waterloo Region..

Ontario

Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.

United States

Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal the PAIRS program is to the development of radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.

United States

Successor-in-Interest (Type 6 Parent Clinical Trial Optional)

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization status, often referred to in this announcement as Successor-In-Interest, may be submitted to this FOA. Applications for change of recipient organization status are considered prior approval requests (as described in Section 8.1.2.8 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although successor-in-interest requests may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

United States

PME MTL – Innovation Program

Non-repayable contribution typically up to $50,000 for eligible innovation activities.

Non-repayable financial contribution to support the development of innovative products, services, or processes in the City of Montreal, including prototyping, validation, and early market testing.

Montreal · Quebec

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)

The goal of this phased FOA (either R33/R61 or UG3/UH3) is to accelerate the development of sensitive biomarkers/tools to predict individual treatment-response between two or more existing treatments for depression. In phase 1 (up to 2 years) preliminary studies (e.g., retrospective secondary analyses of data from completed clinical trials and/or in nimble, fast-fail pilot studies) will de-risk the test technology demonstrating that there is enough signal for clinical utility (futility analyses, ROC curves, and/or effect size will be evaluated as go/no-go criteria). Phase 2 (up to 5 years) innovators will prospectively test the efficacy of the biomarker/tool in large-scale biomarker/tool-stratified clinical trials with the goal of beating standard-of-care decision-making (i.e., clinician/patient treatment assignment will be the CTRL group vs the test).

United States

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-NNN, the R61/R33 option).

United States

Ville de Québec – Fonds local d’investissement (FLI) – Innovation/Numérique Grants

Non-repayable contributions may be available up to $50,000 for innovation/digital projects via local funds (terms vary by MRC).

Supports businesses in Quebec City carrying out innovation and digital transformation initiatives, including software development, process digitization, and commercialization of new technologies.

Quebec City · Quebec

Catalyze: Product Definition Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)

This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

United States

Environmental Health Sciences Core Centers (EHSCC) (P30 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC). As intellectual hubs for environmental health research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/).The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research.

United States

Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed)

The National Institute on Aging (NIA) invites outstanding graduate students from a wide range of broad research areas who are interested in receiving aging-related postdoctoral training to apply to this Funding Opportunity Announcement (FOA). This FOA seeks to foster the development of research and clinician scientists in the following areas: genetic, biological, clinical, epidemiological, neuroscience, behavioral, social, and economic research on aging, both basic and translational. To accomplish the goal, successful applicants will be awarded the Transition to Aging Research Award for Predoctoral Students. The purpose of the award is to recruit and retain emerging investigators in aging research. This two-phase award will allow awardees to complete doctoral dissertation projects and provide a variety of training supports to facilitate the smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions.

United States

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trial Required)

This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include mechanistic studies that are classified as clinical trials. Mechanistic studies are defined as studies with the objective to understand the mechanism(s) of action of an intervention, a biological or behavioral process, or the pathophysiology of a disease/condition. See NOT-AT-20-001 and NOT-MH-19-006 for examples of clinical trials that are/are not considered mechanistic studies. Clinical trials that propose to influence a clinical outcome, test safety or feasibility of an intervention, demonstrate the clinical efficacy or effectiveness of an intervention, or analyze the effect size of an intervention on clinical outcomes are ineligible for this FOA. Types of studies that should submit under this FOA include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Researchers proposing basic science experimental studies involving human participants should consider this FOAs companion for basic experimental studies with humans, TEMP-14931, Research on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required). Applications proposing studies that include, but are not limited to, model animal research or observational studies involving humans should submit under the companion FOA, TEMP-14934, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed).

United States

Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)

The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission.

United States

United Way Grants

50% funding for paid work experience, skill-building, and community impact programs

Grant Goals - Economic recovery support - Employability enhancement - Community resilience building - Skill development for marginalized populations - Emergency response and community support - Social inclusion and connectivity Keywords - Work experience - Skill development - Economic empowerment - Community resilience - Non-profit capacity building - Social support - Employability training - Urgent response - Inclusive employment - Career readiness - Workforce integration - Community development - Social innovation - Skill transfer - Professional development Description United Way British Columbia provides targeted grants to support non-profit organizations across various community sectors. The grants focus on addressing economic challenges, enhancing employability, and building community resilience through strategic funding and support programs. Target Audience - Non-profit organizations - Registered charities - Community service providers - Social impact initiatives - Organizations supporting vulnerable populations - Employment training programs - Community development groups Eligible Expenses - Paid work experience placements - Skills training programs - Mental health support - Community-led event funding - Emergency response provisions - Capacity building initiatives Eligibility - Registered non-profit organizations - Charitable organizations in British Columbia - Programs addressing social support needs - Initiatives targeting economic recovery - Community-focused service delivery Criteria - Alignment with United Way BC mission - Demonstrated community impact - Focus on vulnerable populations - Innovative approach to social challenges - Potential for long-term community benefit - Clear program objectives - Measurable outcomes Program Requirements - Structured work experience placements - Skill development components - Community benefit assessment - Reporting and impact documentation - Alignment with provincial priorities - Participant tracking - Outcome measurement Hiring Criteria - Support for income/disability assistance recipients - Focus on employability enhancement - Hands-on work experience - Skill-building opportunities - Preparation for in-demand jobs Due Dates - Varies by grant stream - Currently closed for Work Experience Opportunities Grant - Periodic funding cycles Start Dates - Dependent on grant stream - Aligned with program development - Responsive to community needs Age Requirements - No specific age restrictions mentioned - Focus on workforce-ready individuals - Emphasis on economic participation Industry / Area of Work - Social services - Community development - Employment training - Emergency response - Mental health support - Skill development - Workforce integration - Non-profit sector - Community resilience - Social innovation

British Columbia

Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.

United States

NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate.. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.

United States

Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

United States

Hudson Testing #2

The CanExport SMEs funding program provides Canadian government grants to support Canadian businesses seeking to develop new export opportunities and markets, particularly high-growth priority markets and sectors, by covering a portion of eligible sales and marketing activities.

Canada

Food Product Development Assistance

50% funding for product development, testing, and technical training in food innovation.

The program contributes 50 per cent of project costs to a maximum contribution of $50,000 per business. Multiple projects may be submitted by one business; however, the maximum approval amount to one business in a twelve month period will not exceed $50,000.

Prince Edward Island

Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This FOA seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.

United States

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

United States

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

United States

Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.

United States

Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and pilot test the navigator models ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as symptoms are detected. Of interest are navigator models that coordinate needed care strategies, determine the personalized match to the level of needed service amount, frequency and intensity, and harness novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes.This FOA is published in parallel to a companion R01 (Currently Temp-11229)

United States

Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)

This R01 funding opportunity encourages projects that test, in animals and/or humans, whether modifying electrophysiological patterns can improve cognitive, affective, or social processing. This R01 FOA is expected to have a companion R21 version. The proximal goal of this FOA (and its companion R21 version) is to encourage investigators to test whether modifying specific patterns of coordinated neural activity in vivo can improve cognitive, social, or affective processes. These studies should be based on a rational understanding of the role of specific neural activity rhythms in, for example, the routing of information among brain regions or in improving the ability of afferent information to affect local processing via coherence of underlying oscillatory activity.

United States

Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration.

United States